Sourcing high-purity Dermorphin for laboratory research requires analytical precision, lot-specific verification, and reliable supplier compliance. PX1 Research provides USA-manufactured Dermorphin synthesized for rigorous in vitro and preclinical investigation.
Sourcing high-purity Dermorphin for laboratory research requires analytical precision, lot-specific verification, and reliable supplier compliance. PX1 Research provides USA-manufactured Dermorphin synthesized for rigorous in vitro and preclinical investigation.
Laboratory researchers seeking high-purity Dermorphin for sale require verified, highly stable analytical standards. Dermorphin is a naturally occurring heptapeptide μ-opioid receptor agonist used strictly in preclinical receptor-binding, signaling pathway, and enzymatic degradation studies. PX1 Research supplies USA-manufactured, research-grade Dermorphin with lot-specific RP-HPLC purity exceeding 98% and documented mass spectrometry verification.
When evaluating options to acquire research-grade Dermorphin, investigators must ensure that material is manufactured under strict quality control frameworks. Dermorphin's unique chemical sequence demands precise solid-phase peptide synthesis (SPPS) and thorough purification to prevent truncated or sequence-modified impurities from skewing binding assay results. PX1 Research delivers analytical-grade materials designed explicitly for controlled laboratory environments.
Dermorphin is a heptapeptide originally isolated from the skin of South American frogs belonging to the genus *Phyllomedusa*. Its primary amino acid sequence is H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2. The most remarkable structural feature of Dermorphin is the inclusion of D-alanine at position 2, a post-translationally modified D-amino acid that is rarely encountered in naturally occurring vertebrate peptides.
The presence of the D-Ala2 residue imparts exceptional conformational stability and steric resistance against cleavage by endogenous aminopeptidases. In preclinical biochemical assays, this structural modification allows Dermorphin to resist rapid enzymatic proteolysis, maintaining structural integrity significantly longer than classical linear L-amino acid peptides. This makes Dermorphin a critical benchmark compound in research exploring peptidomimetic design and peptide stabilization strategies.
In vitro binding assays and functional receptor characterization demonstrate that Dermorphin acts as a potent, highly selective agonist at the μ-opioid receptor (MOR). Quantitative radioligand binding experiments show that Dermorphin exhibits a binding affinity (Ki) for μ-opioid receptors in the sub-nanomolar range, displaying several hundred-fold higher selectivity for MOR over δ-opioid (DOR) and κ-opioid (KOR) receptor subtypes.
Preclinical studies suggest that upon binding to the extracellular pocket of the μ-opioid receptor, Dermorphin induces a conformational shift that recruits G-proteins (Gαi/o subunits) and activates intracellular downstream signaling cascades, including inhibition of adenylyl cyclase activity and modulation of voltage-gated calcium channels. Researchers utilize Dermorphin to study receptor phosphorylation, β-arrestin recruitment dynamics, and receptor endocytosis in heterologous expression systems and primary neuronal cultures.
Dermorphin serves as a vital tool peptide across several non-clinical biological domains. Because of its selective signaling mechanisms and stability, laboratory investigations frequently implement Dermorphin across the following experimental paradigms:
1. **Receptor Ligand Binding and Dimerization Assays**: Dermorphin is regularly employed in competitive radioligand displacement assays and bioluminescence resonance energy transfer (BRET) experiments to evaluate G-protein coupled receptor (GPCR) active states and MOR-DOR homodimer or heterodimer interactions.
2. **Antinociceptive Signaling Pathways in Rodent Models**: In preclinical animal studies, Dermorphin has been investigated to map central versus peripheral pain signaling pathways, spinal cord opioid receptor distribution, and the supraspinal mechanics of nociception.
3. **Peptidase Resistance and Stability Mapping**: Structural biologists evaluate Dermorphin’s D-Ala modification as a reference model when designing synthetic peptidomimetics engineered to survive proteolytic environments without losing receptor affinity.
Researchers exploring related molecular targets can review our broader catalog of research peptides or consult the PX1 research repository for technical references.
To contextualize Dermorphin within peptide research, investigators frequently compare its selectivity, structural conformation, and enzymatic stability against other established receptor ligands. The table below outlines key biochemical differences observed in preclinical literature:
Dermorphin features a D-Ala residue at position 2, offering extremely high μ-opioid selectivity and exceptional enzymatic resistance. In contrast, deltorphin research peptides incorporate D-Met or D-Ala at position 2 within a distinct sequence context that shifts selectivity dramatically toward δ-opioid receptors. Meanwhile, synthetic standard ligands like DAMGO synthetic analogs share high μ-selectivity but differ in structural backbone flexibility.
For structural stability studies evaluating peptidomimetic modifications outside the opioid class, scientists also frequently study compounds like BPC-157 peptide standards, selank neuroactive sequences, or semax synthetic ligands to contrast baseline enzymatic degradation rates across diverse peptide structures.
Dermorphin is supplied as a lyophilized (freeze-dried) powder to maximize chemical stability during transport and storage. To ensure compound integrity and reproducibility in laboratory assays, standard handling guidelines should be followed strictly.
Reconstitution should be performed using sterile, bacteriostatic, or deionized laboratory-grade water, or appropriate buffered solutions such as phosphate-buffered saline (PBS, pH 7.4) depending on assay requirements. Gently swirl or invert the vial until complete dissolution is achieved; avoid violent vortexing or sonication, which can induce mechanical shear stress or aggregation.
Once reconstituted, stock solutions should be aliquoted into single-use polypropylene microcentrifuge tubes to prevent repeated freeze-thaw cycles. Store lyophilized vials long-term at -20°C or -80°C in a desiccated environment. Reconstituted liquid aliquots should be kept at -80°C for extended stability, or at 2°C to 8°C if utilized within a short experimental window (24–48 hours).
When purchasing Dermorphin for analytical research, verifying batch purity and identity is essential for experimental accuracy. PX1 Research subjects every lot of Dermorphin to rigorous independent third-party analytical testing at accredited ISO 17025 laboratories.
Key quality control parameters include Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm peptide purity (>98%), Electrospray Ionization Mass Spectrometry (ESI-MS) to verify exact molecular weight and amino acid composition, and Chromogenic LAL testing to quantify bacterial endotoxin levels. Endotoxin control is particularly critical for cellular assays and in vivo rodent models, where residual lipopolysaccharides (LPS) can trigger non-specific inflammatory responses and obscure experimental findings.
PX1 Research is an established USA-based supplier dedicated exclusively to serving university laboratories, contract research organizations (CROs), and institutional scientists. We maintain strict manufacturing oversight and provide full transparency for every compound listed.
When you order Dermorphin for sale from PX1 Research, you receive:
- **USA Manufacturing & Quality Assurance**: Fully synthesized in GMP-compliant, US-based facilities.
- **Lot-Specific Certificates of Analysis**: Accessible COAs detailing RP-HPLC purity profiles, mass spec chromatograms, and endotoxin values for your exact batch.
- **Rapid Domestic Fulfillments**: Same-day dispatch on orders placed Monday through Friday, shipping directly from our primary distribution hubs in California and Arizona.
- **Institutional Support**: Dedicated account management for high-volume research laboratories and institutional procurement officers via our wholesale lab accounts portal.
What is Dermorphin used for in laboratory research?
Dermorphin is utilized exclusively as a research standard in preclinical and in vitro assays. Common applications include mu-opioid receptor (MOR) binding kinetics, GPCR signaling pathway mapping, peptidomimetic degradation assays, and nociceptive signaling research in animal models.
How does Dermorphin achieve high enzymatic stability?
Dermorphin contains a D-alanine residue at position 2 of its heptapeptide sequence. Endogenous mammalian aminopeptidases specifically target L-amino acid peptide bonds; the D-configuration creates steric hindrance that protects the peptide backbone from rapid enzymatic cleavage.
What purity levels are provided with PX1 Research Dermorphin?
Every lot of Dermorphin supplied by PX1 Research guarantees a minimum purity of 98% as verified by independent Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and mass spectrometry.
Where can I inspect the Certificate of Analysis (COA) for Dermorphin?
Lot-specific Certificates of Analysis are available directly on the PX1 Research website. Each COA provides raw RP-HPLC chromatograms, mass spectrometry molecular weight verification, and endotoxin assay results.
What is the recommended reconstitution procedure for Dermorphin?
Dermorphin lyophilized powder should be reconstituted using sterile laboratory-grade water or buffered saline (PBS, pH 7.4). The vial should be gently swirled until dissolved. Avoid harsh agitation or prolonged vortexing.
How should Dermorphin be stored upon receipt?
Unopened lyophilized Dermorphin should be stored at -20°C or -80°C in a dry, desiccated container. Reconstituted stock solutions should be aliquoted and stored at -80°C to avoid degradation from repeat freeze-thaw cycles.
What is the shipping location and timeline for PX1 Research orders?
All orders ship directly from PX1 Research facilities located in California and Arizona. Orders placed Monday through Friday before our daily cutoff time are dispatched the same day.
Is Dermorphin approved for human consumption or clinical use?
No. Dermorphin provided by PX1 Research is strictly designated for laboratory research use only (in vitro and preclinical models). It is not for human or animal therapeutic, diagnostic, or clinical applications.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.